Evidence map›Paper›PMID 33941700›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

Physical tuning of galectin-3 signaling.

Shaheen A Farhadi, Renjie Liu, Matthew W Becker, Edward A Phelps, Gregory A Hudalla

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. The Role of Galectin-3 in Liver Inflammation and Fibrosis.Journal of inflammation research · 2026
    Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Supramolecular assembly of multifunctional protein gels via anMolecular systems design & engineering · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Shaheen A FarhadiJ. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL 32611.ORCID 0000-0003-0361-3200
Renjie LiuJ. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL 32611.ORCID 0000-0002-3885-244X
Matthew W BeckerJ. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL 32611.ORCID 0000-0002-3071-7171
Edward A PhelpsJ. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL 32611.ORCID 0000-0001-8666-805X
Gregory A HudallaJ. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL 32611 ghudalla@bme.ufl.edu.ORCID 0000-0003-2259-0809
University of Florida · US

Funding

Using social networks to map and evaluate team science across CTSA hubsUL1TR001427 · NCATS · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A. · 2015 to 2024
$37.2M
Together: Transforming and Translating Discovery to Improve HealthTL1TR001428 · NCATS · UNIVERSITY OF FLORIDA · PI MCCORMACK, WAYNE T. · 2015 to 2023
$3.9M
Tissue-Targeted Enzyme for Localized Tryptophan Catabolism to Direct Subcutaneous and Oral Mucosal Inflammatory ResponsesR01DE027301 · NIDCR · UNIVERSITY OF FLORIDA · PI KESELOWSKY, BENJAMIN GEORGE · 2017 to 2020
$2.0M
Mechanism and dynamics of islet GABA signalingR01DK124267 · NIDDK · UNIVERSITY OF FLORIDA · PI PHELPS, EDWARD · 2021 to 2025
$1.8M
Modular Nanomedicines Based on Heterogeneous Fusion Protein Co-AssemblyR03EB019684 · NIBIB · UNIVERSITY OF FLORIDA · PI HUDALLA, GREGORY · 2015 to 2016
$141k
Engineered tolerogenic exosomes for treating type 1 diabetes autoimmunityF31DK126397 · NIDDK · UNIVERSITY OF FLORIDA · PI BECKER, MATTHEW · 2020 to 2022
$100k
NCATS NIH HHS TL1 TR001428NCATS NIH HHS UL1 TR001427NIBIB NIH HHS R03 EB019684NIDCR NIH HHS R01 DE027301NIDDK NIH HHS F31 DK126397NIDDK NIH HHS R01 DK124267
6 · The paper itself

Abstract

Galectin-3 (Gal3) exhibits dynamic oligomerization and promiscuous binding, which can lead to concomitant activation of synergistic, antagonistic, or noncooperative signaling pathways that alter cell behavior. Conferring signaling pathway selectivity through mutations in the Gal3-glycan binding interface is challenged by the abundance of common carbohydrate types found on many membrane glycoproteins. Here, employing alpha-helical coiled-coils as scaffolds to create synthetic Gal3 constructs with defined valency, we demonstrate that oligomerization can physically regulate extracellular signaling activity of Gal3. Constructs with 2 to 6 Gal3 subunits ("Dimer," "Trimer," "Tetramer," "Pentamer," "Hexamer") demonstrated glycan-binding properties and cell death-inducing potency that scaled with valency. Dimer was the minimum functional valency. Unlike wild-type Gal3, which signals apoptosis and mediates agglutination, synthetic Gal3 constructs induced cell death without agglutination. In the presence of CD45, Hexamer was distributed on the cell membrane, whereas it clustered in absence of CD45 via membrane glycans other than those found on CD7. Wild-type Gal3, Pentamer, and Hexamer required CD45 and CD7 to signal apoptosis, and the involvement of caspases in apoptogenic signaling was increased in absence of CD45. However, wild-type Gal3 depended on caspases to signal apoptosis to a greater extent than Hexamer, which had greater caspase dependence than Pentamer. Diminished caspase activation downstream of Hexamer signaling led to decreased pannexin-1 hemichannel opening and interleukin-2 secretion, events facilitated by the increased caspase activation downstream of wild-type Gal3 signaling. Thus, synthetic fixation of Gal3 multivalency can impart physical control of its outside-in signaling activity by governing membrane glycoprotein engagement and, in turn, intracellular pathway activation.

Indexed as

ApoptosisBlood ProteinsCell DeathCell Line, TumorGalectinsHumansJurkat CellsLactoseLeukocyte Common AntigensMicroscopy, ConfocalPolysaccharidesProtein BindingProtein MultimerizationSignal TransductionT-LymphocytesBlood ProteinsGalectinsLactoseLeukocyte Common AntigensLGALS3 protein, humanPolysaccharidescoiled-coilemergent functiongalectin-3multivalencysignal transduction

Identifiers

PMID33941700
PMCPMC8126866
OpenAlexW3159360090

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.